nach oben

CNS Drugs

Erschienen in:

01.11.2005 | Review Article

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

verfasst von: Dr Richard P. Malone, Silvia S. Gratz, Mary Anne Delaney, Susan B. Hyman

Erschienen in: CNS Drugs | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

Autism is a disorder characterised by abnormalities in language and social development, and repetitive behaviours. Antipsychotics, including haloperidol and risperidone, are the most widely studied drugs for reducing symptoms in children and adolescents with autism. When administered at relatively low dosages, antipsychotics have been shown to reduce repetitive behaviours (stereotypies) and social withdrawal, as well as a number of related symptoms, such as hyperactivity, aggression, self-abusive behaviour, temper tantrums, lability of mood and irritability. Adverse effects of antipsychotics include sedation, dizziness, increased appetite, weight gain, changes in the electrocardiogram parameters, drooling, hyperprolactinemia and a risk of drug-related dyskinesias.

Other agents have been less well studied for the treatment of autism, but there are suggestive data regarding their safety and efficacy. Of these agents, a number have been investigated, based on theories about the aetiology of autism, including SSRIs and naltrexone, although the efficacy of these agents has been limited. Stimulant drugs have been shown to reduce hyperactivity and improve focus, but they may cause behavioural worsening, weight loss and stereotypies de novo. Secretin is a treatment that has received much media attention after reports of efficacy from small open studies, but all controlled studies have failed to show any benefit. In autism, alternative treatments have also been used, but none have shown benefit in well-designed studies.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347(5): 314–21PubMedCrossRef

Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19(2): 227–39PubMedCrossRef

Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141(10): 1195–202PubMed

Naruse H, Nagahata M, Nakane Y, et al. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982; 48(4): 173–84PubMed

Cohen IL, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 1980; 19(4): 665–77PubMedCrossRef

Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1978; 17(4): 640–55PubMedCrossRef

Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30(3): 582–9PubMedCrossRef

McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30(5): 427–35PubMedCrossRef

10.

Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30(3): 245–55PubMedCrossRef

11.

Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25(3): 283–94PubMedCrossRef

12.

Campbell M, Small AM, Collins P, et al. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 1976; 19(1): 70–86PubMed

13.

Campbell M, Fish B, Raphael D, et al. Response to triiodothyronine and dextroamphetamine: a study of pre-school schizophrenic children. J Autism Child Schizophr 1972; 2(4): 343–58PubMedCrossRef

14.

Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53(3): 77–82PubMed

15.

Jaselskis CA, Cook Jr EH, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12(5): 322–7PubMedCrossRef

16.

Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39(12): 1023–31PubMedCrossRef

17.

Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children: a double-blind placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995; 34(2): 223–31PubMedCrossRef

18.

Bouvard MR, Peboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 1995; 58: 191–201PubMedCrossRef

19.

Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Psychiatry 1993; 32(6): 1283–91CrossRef

20.

Unis AS, Munson JA, Rogers SJ, et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry 2002; 41(11): 1315–21PubMedCrossRef

21.

Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics 2001; 107(5): E71. Available from URL: http://www.pediatrics.Org/cgi/content/full/107/5/e71 [Accessed 2005 Sep 28]PubMedCrossRef

22.

Owley T, McMahon W, Cook EH, et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 2001; 40(11): 1293–9PubMedCrossRef

23.

Coniglio SJ, Lewis JD, Lang C, et al. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 2001; 138(5): 649–55PubMedCrossRef

24.

Sandier AD, Sutton KA, DeWeese J, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 1999; 341(24): 1801–6CrossRef

25.

Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28(1): 87–92PubMedCrossRef

26.

Campbell M, Schopler E, Cueva JE, et al. Treatment of autistic disorder. Am J Psychiatry 1996; 35(2): 134–43

27.

Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36(6): 835–43PubMedCrossRef

28.

Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50(2): 171–4PubMed

29.

Demb HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities [letter]. J Child Adolesc Psychopharmacol 1996; 6(1): 79–80PubMedCrossRef

30.

Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33(1): 155–9PubMed

31.

Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6(3): 177–90PubMedCrossRef

32.

Hardan A, Johnson K, Johnson C, et al. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35(11): 1551–6PubMedCrossRef

33.

Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997; 27(3): 313–23PubMedCrossRef

34.

Masi G, Cosenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001; 40(10): 1206–14PubMedCrossRef

35.

Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002; 41(2): 140–7PubMedCrossRef

36.

McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive develop-mental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36(5): 685–93PubMedCrossRef

37.

Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37(4): 372–6PubMedCrossRef

38.

Perry R, Pataki C, Munoz-Silva DM, et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997; 7(3): 167–79PubMedCrossRef

39.

Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825–35PubMed

40.

Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13(1): 25–40PubMedCrossRef

41.

Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85(4): 295–305PubMedCrossRef

42.

Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004; 161(5): 918–20PubMedCrossRef

43.

Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40(8): 887–94PubMedCrossRef

44.

Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11): 1686–96PubMed

45.

Malone RP, Delaney MA, Gifford C. Ziprasidone treatment-associated changes in QTc and weight in adolescents with autism. 50th Annual Meeting of the American Academy of Child & Adolescent Psychiatry Scientific Proceedings; 2003 Oct 14–19; Washington, DC: AACAP 2003: 154

46.

McDougle CJ, Kern DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8): 921–7PubMedCrossRef

47.

Federal Drug Administration. Psychopharmacological Drugs Advisory Committee; 2000 Jul 19. Briefing document for zeldox capsules (Ziprasidone HCL) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619bla.pdf [Accessed 2005 Oct 3]

48.

Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on the QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24(1): 62–9PubMedCrossRef

49.

Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9(2): 99–107PubMedCrossRef

50.

Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14(2): 287–94PubMedCrossRef

51.

Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci 2001; 26(4): 340–1PubMed

52.

Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996; 153(5): 738PubMed

53.

Deykin EY, MacMahon B. The incidence of seizures among children with autistic symptoms. Am J Psychiatry 1979; 136(10): 1310–2PubMed

54.

Rutter M, Greenfeld D, Lockyer L. A five to fifteen year follow-up study of infantile psychosis: II. social and behavioural outcome. Br J Psychiatry 1967; 113(504): 1183–99PubMedCrossRef

55.

Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50(6): 441–7PubMedCrossRef

56.

Sanchez LE, Campbell M, Small AM, et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 537–44PubMedCrossRef

57.

Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled crossover study. J Clin Psychopharmacol 2001; 21(4): 440–4PubMedCrossRef

58.

Cook Jr EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31(4): 739–45PubMedCrossRef

59.

Fatemi SH, Realmuto GM, Khan L, et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998; 28(4): 303–7PubMedCrossRef

60.

DeLong RG, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002; 44(10): 652–9PubMedCrossRef

61.

Courturier JL, Nicholson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2002; 12(3): 243–8CrossRef

62.

Namerow LB, Thomas P, Bostic JQ, et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003; 24(2): 104–8PubMedCrossRef

63.

Hollander E, Kaplan A, Cartwright C, et al. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 2000; 15(2): 132–5PubMedCrossRef

64.

McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53(11): 1001–8PubMedCrossRef

65.

Federal Drug Administration. FDA Talk Paper; 2003 Jun 19. FDA statement regarding the anti-depressant Paxil for pediatric population [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01230.html [Accessed 2005 Oct 3]

66.

Federal Drug Administration. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004_4065b1/htn [Accessed 2005 Oct 3]

67.

Campbell M, Overall JE, Small AM, et al. Naltrexone in autistic children: an acute dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989; 28(2): 200–6PubMedCrossRef

68.

Gillberg C, Terenius L, Lonnerholm G. Endorphin activity in childhood psychosis: spinal fluid levels in 24 cases. Arch Gen Psychiatry 1985; 42(8): 780–3PubMedCrossRef

69.

Panksepp J, Sahley TL. Possible brain opioid involvement in disrupted social intent and language development in autism. In: Schopler E, Mesibov GB, editors. Neurobiological issues in autism. New York: Plenum, 1987: 357–72

70.

Leboyer M, Bouvard MP, Launay JM, et al. Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord 1992; 22(2): 309–19PubMedCrossRef

71.

Campbell M, Harris JC. Resolved: autistic children should have a trial of naltrexone. J Am Acad Child Adolesc Psychiatry 1996; 35(2): 246–9PubMedCrossRef

72.

Willemsen-Swinkeis SH, Buitelaar JK, Nijhof GJ, et al. Failure of naltrexone hydrochloride to reduce self injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies. Arch Gen Psychiatry 1995; 52(9): 766–73CrossRef

73.

Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158(7): 1067–74PubMedCrossRef

74.

Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58(4): 527–36CrossRef

75.

McQueen JM, Heck AM. Secretin for the treatment of autism. Ann Pharmacother 2002; 36(2): 305–11PubMedCrossRef

76.

Phase 3 study for autism fails to meet dual primary endpoints. Development of secretin for schizophrenia to continue. Repligen [information release]. Waltham (MA): 2004 Jan 5

77.

McEvoy GK, editor. AHFS drug information. Bethesda (MD): American Society of Health System Pharmacists Inc, 1999

78.

Horvath K, Stefanatos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998; 9(1): 9–15PubMed

79.

Chez MG, Buchanan CP, Bagan BT, et al. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 2000; 30(2): 87–94PubMedCrossRef

80.

Corbett B, Khan K, Czapansky-Beilman D, et al. A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism. Clin Pediatr 2001; 40(6): 327–31CrossRef

81.

Carey T, Ratliff-Schaub K, Funk J, et al. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. J Autism Dev Disord 2002; 32(3): 161–7PubMedCrossRef

82.

Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002; 12(3): 237–41PubMedCrossRef

83.

Insel TR, O’Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry 1999; 45(2): 145–57PubMedCrossRef

84.

Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology 2003; 28(1): 193–8PubMedCrossRef

85.

Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry 1978; 135(4): 472–5PubMed

86.

Lelord G, Muh JP, Barthelemy C, et al. Effects of pyridoxine and magnesium on autistic symptoms: initial observations. J Autism Dev Disord 1981; 11(2): 219–30PubMedCrossRef

87.

Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry 1985; 20(5): 467–78PubMedCrossRef

88.

Findling RL, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 1997: 27(4) 467–78PubMedCrossRef

89.

Tolbert L, Haigler T, Waits MM, et al. Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord 1993; 23(1): 193–9PubMedCrossRef

90.

Pfeiffer SI, Norton J, Nelson L, et al. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord 1995; 25(5): 481–93PubMedCrossRef

91.

Rimland B. Critique of “Efficacy of vitamin B6 and magnesium in the treatment of autism”. J Autism Dev Disord 1998; 28(6): 580–1PubMed

92.

Knivsberg AM, Wiig K, Lind G, et al. Dietary intervention in autistic syndromes. Developmental Brain Dysfunction 1990; 3: 315–27

93.

Reichelt KL, Knivsberg AM, Nodland M, et al. Nature and consequences of hyperpeptiduria and bovine casomorphins found in autistic syndromes. Developmental Brain Dysfunction 1994; 7: 71–85

94.

Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002; 5(4): 251–61PubMedCrossRef

Titel: Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders
verfasst von: Dr Richard P. Malone
Silvia S. Gratz
Mary Anne Delaney
Susan B. Hyman
Publikationsdatum: 01.11.2005
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 11/2005
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200519110-00003

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2005

Rotigotine

Overtreatment in Epilepsy

Head-To-Head Comparison of the Costs of Atypical Antipsychotics

The Use of Triptans in the Management of Menstrual Migraine